| Scrip Code | 500201 |
|---|---|
| NSE Symbol | INDIAGLYCO |
| MSEI Symbol | NOTLISTED |
| ISIN | INE560A01023 |
| Name of company | INDIA GLYCOLS LIMITED |
| Type of company | Main Board |
| Class of security | Equity |
| Date of start of financial year | 01-04-2025 |
| Date of end of financial year | 31-03-2026 |
| Date of board meeting when results were approved | 10-02-2026 |
| Date on which prior intimation of the meeting for considering financial results was informed to the exchange | 03-02-2026 |
| Description of presentation currency | INR |
| Level of rounding used in financial results | Lakhs |
| Reporting Type | Quarterly |
| Reporting Quarter | Third quarter |
| Nature of report standalone or consolidated | Standalone |
| Whether results are audited or unaudited for the quarter ended | Unaudited |
| Whether results are audited or unaudited for the Year to date for current period ended/year ended | Unaudited |
| Segment Reporting | Multi segment |
| Description of single segment | |
| Start date and time of board meeting | 10-02-2026 16:00:00 |
| End date and time of board meeting | 10-02-2026 17:12:00 |
| Whether cash flow statement is applicable on company | |
| Type of cash flow statement | |
| Declaration of unmodified opinion or statement on impact of audit qualification | Not applicable |
| Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? | Yes |
| No. of times funds raised during the quarter | 1 |
| Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? | No |
| During the year Company has not made any default on Loans and Debt securities. | |
| Particulars | 3 months/ 6 months ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |
|---|---|---|---|
| A | Date of start of reporting period | 01-10-2025 | 01-04-2025 |
| B | Date of end of reporting period | 31-12-2025 | 31-12-2025 |
| C | Whether results are audited or unaudited | Unaudited | Unaudited |
| D | Nature of report standalone or consolidated | Standalone | Standalone |
| 1 | Income | ||
| Revenue from operations | 2,55,106.00 | 7,46,480.00 | |
| Other income | 74.00 | 431.00 | |
| Total income | 2,55,180.00 | 7,46,911.00 | |
| 2 | Expenses | ||
| (a) | Cost of materials consumed | 59,782.00 | 1,92,777.00 |
| (b) | Purchases of stock-in-trade | 4,081.00 | 14,821.00 |
| (c) | Changes in inventories of finished goods, work-in-progress and stock-in-trade | 5,307.00 | (2,259.00) |
| (d) | Employee benefit expense | 3,477.00 | 9,701.00 |
| (e) | Finance costs | 4,681.00 | 14,077.00 |
| (f) | Depreciation, depletion and amortisation expense | 4,122.00 | 11,415.00 |
| (f) | Other Expenses | ||
| 1 | Excise Duty | 1,44,870.00 | 4,23,156.00 |
| 2 | Power and Fuel | 10,579.00 | 31,281.00 |
| 3 | Other Expenses | 9,368.00 | 28,767.00 |
| Total other expenses | 1,64,817.00 | 4,83,204.00 | |
| Total expenses | 2,46,267.00 | 7,23,736.00 | |
| 3 | Total profit before exceptional items and tax | 8,913.00 | 23,175.00 |
| 4 | Exceptional items | (83.00) | (83.00) |
| 5 | Total profit before tax | 8,830.00 | 23,092.00 |
| 6 | Tax expense | ||
| 7 | Current tax | 1,291.00 | 3,020.00 |
| 8 | Deferred tax | 1,013.00 | 2,867.00 |
| 9 | Total tax expenses | 2,304.00 | 5,887.00 |
| 10 | Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement | 0.00 | 0.00 |
| 11 | Net Profit Loss for the period from continuing operations | 6,526.00 | 17,205.00 |
| 12 | Profit (loss) from discontinued operations before tax | 0.00 | 0.00 |
| 13 | Tax expense of discontinued operations | 0.00 | 0.00 |
| 14 | Net profit (loss) from discontinued operation after tax | 0.00 | 0.00 |
| 15 | Share of profit (loss) of associates and joint ventures accounted for using equity method | 0.00 | 0.00 |
| 16 | Total profit (loss) for period | 6,526.00 | 17,205.00 |
| 17 | Other comprehensive income net of taxes | (19.00) | (56.00) |
| 18 | Total Comprehensive Income for the period | 6,507.00 | 17,149.00 |
| 19 | Total profit or loss, attributable to | ||
| Profit or loss, attributable to owners of parent | |||
| Total profit or loss, attributable to non-controlling interests | |||
| 20 | Total Comprehensive income for the period attributable to | ||
| Comprehensive income for the period attributable to owners of parent | |||
| Total comprehensive income for the period attributable to owners of parent non-controlling interests | |||
| 21 | Details of equity share capital | ||
| Paid-up equity share capital | 3,351.00 | 3,351.00 | |
| Face value of equity share capital | 5 | 5 | |
| 27 | Details of debt securities | ||
| 22 | Reserves excluding revaluation reserve | ||
| 23 | Earnings per share | ||
| i | Earnings per equity share for continuing operations | ||
| Basic earnings (loss) per share from continuing operations | 10.42 | 27.47 | |
| Diluted earnings (loss) per share from continuing operations | 10.42 | 27.47 | |
| ii | Earnings per equity share for discontinued operations | ||
| Basic earnings (loss) per share from discontinued operations | 0 | 0 | |
| Diluted earnings (loss) per share from discontinued operations | 0 | 0 | |
| ii | Earnings per equity share | ||
| Basic earnings (loss) per share from continuing and discontinued operations | 10.42 | 27.47 | |
| Diluted earnings (loss) per share from continuing and discontinued operations | 10.42 | 27.47 | |
| 24 | Debt equity ratio | ||
| 25 | Debt service coverage ratio | ||
| 26 | Interest service coverage ratio | ||
| 27 | Disclosure of notes on financial results | Textual Information(1) | |
| Textual Information(1) | Note on Financial Results: At point no.21: 'The Board of Directors of the Company at their meeting held on 16th October, 2025 had considered and approved the raising funds through issuance of 51,03,765 Equity Shares, of face value of Rs. 5/- (Rupees Five) each, at a price of Rs. 915/- per Equity Share, (including a premium of Rs. 910/- per equity share), determined in accordance with provisions of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, for cash, for an aggregate amount of up to Rs. 4,66,99,44,975/- on preferential basis and the same has been approved by the Shareholders of the Company at their Extra Ordinary General Meeting held on 12th November, 2025. The Preferential Allotment Committee of the Board completed the allotment of the aforesaid equity shares to the respective allottee on 24th November, 2025 and the Company's paid up share capital was accordingly increased to Rs. 33,51,33,825/-. The Listing and Trading approvals from the Stock exchanges for above acquired equity shares were obtained on 5th January, 2026 effective from 6th January, 2026.' 'Face value of equity share capital' of Rs.5 is the Face value per equity share.' |
|---|
| Debt equity ratio | |
|---|---|
| Debt service coverage ratio | |
| Interest service coverage ratio |
| Particulars | 3 months/ 6 month ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |||||
|---|---|---|---|---|---|---|---|
| Date of start of reporting period | 01-10-2025 | 01-04-2025 | |||||
| Date of end of reporting period | 31-12-2025 | 31-12-2025 | |||||
| Whether results are audited or unaudited | Unaudited | Unaudited | |||||
| Nature of report standalone or consolidated | Standalone | Standalone | |||||
| 1 | Segment Revenue (Income) | ||||||
| (net sale/income from each segment should be disclosed) | |||||||
| 1 | Bio-based Specialities and Performance Chemicals | 31,298.00 | 89,952.00 | ||||
| 2 | Potable Spirits | 1,79,346.00 | 5,25,634.00 | ||||
| 3 | Ennature Biopharma | 5,034.00 | 14,428.00 | ||||
| 4 | Bio-Fuel | 39,428.00 | 1,16,466.00 | ||||
| Total Segment Revenue | 2,55,106.00 | 7,46,480.00 | |||||
| Less: Inter segment revenue | 0.00 | 0.00 | |||||
| Revenue from operations | 2,55,106.00 | 7,46,480.00 | |||||
| 2 | Segment Result | ||||||
| Profit (+) / Loss (-) before tax and interest from each segment | |||||||
| 1 | Bio-based Specialities and Performance Chemicals | 4,113.00 | 10,380.00 | ||||
| 2 | Potable Spirits | 7,243.00 | 21,715.00 | ||||
| 3 | Ennature Biopharma | 204.00 | 422.00 | ||||
| 4 | Bio-Fuel | 3,299.00 | 8,502.00 | ||||
| Total Profit before tax | 14,859.00 | 41,019.00 | |||||
| i. Finance cost | 4,681.00 | 14,077.00 | |||||
| ii. Other Unallocable Expenditure net off Unallocable income | 1,348.00 | 3,850.00 | |||||
| Profit before tax | 8,830.00 | 23,092.00 | |||||
| 3 | (Segment Asset - Segment Liabilities) | ||||||
| Segment Asset | |||||||
| 1 | Bio-based Specialities and Performance Chemicals | 3,37,141.00 | 3,37,141.00 | ||||
| 2 | Potable Spirits | 61,474.00 | 61,474.00 | ||||
| 3 | Ennature Biopharma | 43,121.00 | 43,121.00 | ||||
| 4 | Bio-Fuel | 1,34,788.00 | 1,34,788.00 | ||||
| Total Segment Asset | 5,76,524.00 | 5,76,524.00 | |||||
| Un-allocable Assets | 6,272.00 | 6,272.00 | |||||
| Net Segment Asset | 5,82,796.00 | 5,82,796.00 | |||||
| 4 | Segment Liabilities | ||||||
| Segment Liabilities | |||||||
| 1 | Bio-based Specialities and Performance Chemicals | 71,928.00 | 71,928.00 | ||||
| 2 | Potable Spirits | 30,255.00 | 30,255.00 | ||||
| 3 | Ennature Biopharma | 7,299.00 | 7,299.00 | ||||
| 4 | Bio-Fuel | 7,440.00 | 7,440.00 | ||||
| Total Segment Liabilities | 1,16,922.00 | 1,16,922.00 | |||||
| Un-allocable Liabilities | 2,18,017.00 | 2,18,017.00 | |||||
| Net Segment Liabilities | 3,34,939.00 | 3,34,939.00 | |||||
| Disclosure of notes on segments | Textual Information(2) | ||||||
| Textual Information(2) | Note1: Since there is no option to fill 'Exceptional Items' in the utility, the same is clubbed with 'Unallocated corporate expenses net of unallocable income'. |
|---|
| Particulars | 3 months/ 6 months ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |
|---|---|---|---|
| A | Date of start of reporting period | 01-10-2025 | 01-04-2025 |
| B | Date of end of reporting period | 31-12-2025 | 31-12-2025 |
| C | Whether results are audited or unaudited | Unaudited | Unaudited |
| D | Nature of report standalone or consolidated | Standalone | Standalone |
| Other comprehensive income [Abstract] | |||
| 1 | Amount of items that will not be reclassified to profit and loss | ||
| 1 | Items that will not be reclassified to profit and loss | (25.00) | (75.00) |
| Total Amount of items that will not be reclassified to profit and loss | (25.00) | (75.00) | |
| 2 | Income tax relating to items that will not be reclassified to profit or loss | (6.00) | (19.00) |
| 3 | Amount of items that will be reclassified to profit and loss | ||
| Total Amount of items that will be reclassified to profit and loss | |||
| 4 | Income tax relating to items that will be reclassified to profit or loss | 0.00 | 0.00 |
| 5 | Total Other comprehensive income | (19.00) | (56.00) |
| Mode of Fund Raising | Preferential Issues |
|---|---|
| Description of mode of fund raising (Applicable in case of others is selected) | |
| Date of Raising Funds | 24-11-2025 |
| Amount Raised | 46,699.00 |
| Report filed for Quarter ended | 31-12-2025 |
| Monitoring Agency | Applicable |
| Monitoring Agency Name, if applicable | CARE Ratings Limited |
| Is there a Deviation / Variation in use of funds raised | No |
| If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders | |
| If Yes, Date of shareholder Approval | |
| Explanation for the Deviation / Variation | |
| Comments of the Audit Committee after review | No Comments |
| Comments of the auditors, if any |
| Sr. | Original Object | Modified Object, if any | Original Allocation | Modified allocation, if any | Funds Utilised | Amount of Deviation/Variation for the quarter according to applicable object | Remarks if any |
| 1 | To augment the fund requirement towards Working Capital of the Company | NA | 35,025.00 | 0.00 | 35,025.00 | 0.00 | During Q3FY26, the company has utilised the part of the proceeds towards repayment of working capital demand loans, cc utilisation and other short-term borrowings, towards the stated object of augmentation of funds towards working capital of the Company, Further, the object doesn't specify the usage of funds towards working capital borrowings reduction. |
| 2 | General Corporate Purposes | NA | 11,674.00 | 0.00 | 11,674.00 | 0.00 | During Q3FY26, The company has transferred the issue proceeds from the monitoring account directly into its SBI CC Account and further utilised the funds of Rs. 116.74 crore towards repayment of instalments for Term Loans during Q3FY26. |
| Name of signatory | Anand Singhal |
| Designation of person | Chief Financial Officer |
| Place | Noida |
| Date | 10-02-2026 |